Skip to main content
Equibles
INTS logo

INTS · Intensity Therapeutics, Inc. · Metrics

Track INTS — free

Use INTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.24 -0.01 (-0.31%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the cash and cash equivalents as of June 30, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$10.61M
Shares
3.26M
Volume · Oct 26 401 Avg daily vol (3M) 26.02K

INTS metrics

50 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.25
Market cap
$10.61M

Price action

20 metrics
Price change (1W)
-3.0%
Price change (30D)
-11.0%
Price change (3M)
-27.0%
Price change (6M)
-38.1%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
60.4%
Annualized volatility (3M)
62.9%
Beta
0.8
RSI (14D)
39.5
Price vs SMA 50
-15.9%
Price vs SMA 200
—
Avg volume (3M)
26,016
Relative volume
0.3
Average dollar volume
$106,027

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.2
reciprocal yield 86.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-105.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-12-31
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.48M
Net income (TTM)
−$11.16M
Trailing 12 months
Diluted EPS (TTM)
$-1.76
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.70

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+258.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-121.2%
Return on assets
-96.9%
Debt / equity
—
Current ratio
5.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.53M
Latest balance sheet
Cash & equivalents
$9.53M
Total assets
$11.52M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.95M
Capital expenditures (TTM)
—
R&D (TTM)
$6.08M
SG&A (TTM)
—
Stock compensation (TTM)
$1.70M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
17
13F filer change QoQ
+3
Institutional ownership
35.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
2.4%
Private-fund adviser ownership
1.5%
Active holders' share change QoQ
+765.5%
Holder tenure
2.2
Price vs estimated holder cost
-12.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
1.2%
Latest settlement · 2.1 days to cover
Days to cover
2.1d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1567264 CUSIP 45828J202 13F (30d) 2 filings 2 filers Visit website Investor relations